ID

42064

Beschreibung

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine; ODM derived from: https://clinicaltrials.gov/show/NCT00058799

Link

https://clinicaltrials.gov/show/NCT00058799

Stichworte

Versionen (2)
  1. 11.04.16 11.04.16 -
  2. 15.03.21 15.03.21 - Dr. rer. medic Philipp Neuhaus
Hochgeladen am

15. März 2021

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Leukemia NCT00058799

Englisch

Eligibility Leukemia NCT00058799

1 Formulare  
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00058799
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients less than or equal to 75 years old with lymphoid (pre-b, b, t, non b-, non t, or burkitt if bone marrow blasts > 20%) or acute myeloid leukemia (m0 to m7) or myelodysplastic syndrome and with: disease that has entered remission with chemotherapy and/or bone marrow transplantation, but is considered to be at high risk of relapse. or primary, or relapsed treatment-refractory disease who, at the time of reinjection of the tumor vaccine, are at a state of complete or partial cytological remission disease (<20% blasts infiltrating the bone marrow) after a second/higher line of conventional and/or high dose chemotherapy.
Beschreibung

Patient and disease status

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0023449
UMLS CUI [3]
C0023467
UMLS CUI [4]
C1982687
UMLS CUI [5]
C3463824
UMLS CUI [6]
C0544452
UMLS CUI [7]
C0392920
UMLS CUI [8]
C0005961
UMLS CUI [9]
C0277556
UMLS CUI [10]
C1328050
2. patients must have a life expectancy of at least 10 weeks.
Beschreibung

Life expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
3. patients must have ecog performance status of 0-2 as below:
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
4. patients must have recovered from the toxic effects of all prior chemotherapy before entering this study, and have an absolute neutrophil count >500/mm3, absolute lymphocyte count >200/mm3, and platelet count >50,000/mm3.
Beschreibung

Toxic effects of chemotherapy and laboratory parameters

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0392920
UMLS CUI [1,3]
C2004454
UMLS CUI [2]
C0948762
UMLS CUI [3]
C3544087
UMLS CUI [4]
C0032181
5. patients must not have active gvhd at the time of protocol entry.
Beschreibung

GvHD

Datentyp

boolean

Alias
UMLS CUI [1]
C0018133
6. patient has not received high dose steroids within the last week or other immunosuppressive drugs within a week (or longer as indicated by the half life of the agent)
Beschreibung

Immunosuppressive therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0038317
UMLS CUI [2]
C0021081
UMLS CUI [3]
C3173309
7. patients must not be infected at time of protocol entry, and should not be receiving antibiotics (other than prophylactic septra.)
Beschreibung

Infections and antibiotics

Datentyp

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2]
C0003232
8. patients must not be hiv-positive.
Beschreibung

HIV Seronegativity

Datentyp

boolean

Alias
UMLS CUI [1]
C0019698
9. patients must have adequate liver function (bilirubin<1.5 mg% sgot<2x normal, normal prothrombin time).
Beschreibung

Bilirubin, sgot and prothrombin time

Datentyp

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0201899
UMLS CUI [3]
C0033707
10. patients must have transduced cells available that are demonstrably >20% cd40l expressing fibroblasts and producing>150 pg il-2/10 6 cell/24 hr.
Beschreibung

Specification: transduced cells

Datentyp

boolean

Alias
UMLS CUI [1]
C0167627
UMLS CUI [2]
C0021756
UMLS CUI [3]
C0085295
11. patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. patients or their guardians will be given a copy of the consent form.
Beschreibung

Informed consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
12. patient must not have received treatment with other investigational agents within the last 4 weeks.
Beschreibung

Experimental drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C0304229
13. patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded. the male partner should use a condom.
Beschreibung

Contraception

Datentyp

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. rapidly progressive/refractory disease (>20% blasts infiltrating the bone marrow)
Beschreibung

Blasts infiltrating bone marrow

Datentyp

boolean

Alias
UMLS CUI [1]
C1982687
2. life expectancy < 10 weeks
Beschreibung

Life expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
3. active infection
Beschreibung

Active infection

Datentyp

boolean

Alias
UMLS CUI [1]
C0009450
4. need for concomitant drugs except analgesics
Beschreibung

Concomitant drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C2347852
UMLS CUI [2,1]
C0332300
UMLS CUI [2,2]
C0002771
5. pregnancy or lactation
Beschreibung

Gynaecological status

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
6. seropositive for hiv
Beschreibung

HIV seropositivity

Datentyp

boolean

Alias
UMLS CUI [1]
C0019699
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Leukemia NCT00058799

1 Formulare
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT00058799
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Patient and disease status
Item
1. patients less than or equal to 75 years old with lymphoid (pre-b, b, t, non b-, non t, or burkitt if bone marrow blasts > 20%) or acute myeloid leukemia (m0 to m7) or myelodysplastic syndrome and with: disease that has entered remission with chemotherapy and/or bone marrow transplantation, but is considered to be at high risk of relapse. or primary, or relapsed treatment-refractory disease who, at the time of reinjection of the tumor vaccine, are at a state of complete or partial cytological remission disease (<20% blasts infiltrating the bone marrow) after a second/higher line of conventional and/or high dose chemotherapy.
boolean
C0001779 (UMLS CUI [1])
C0023449 (UMLS CUI [2])
C0023467 (UMLS CUI [3])
C1982687 (UMLS CUI [4])
C3463824 (UMLS CUI [5])
C0544452 (UMLS CUI [6])
C0392920 (UMLS CUI [7])
C0005961 (UMLS CUI [8])
C0277556 (UMLS CUI [9])
C1328050 (UMLS CUI [10])
Life expectancy
Item
2. patients must have a life expectancy of at least 10 weeks.
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
3. patients must have ecog performance status of 0-2 as below:
boolean
C1520224 (UMLS CUI [1])
Toxic effects of chemotherapy and laboratory parameters
Item
4. patients must have recovered from the toxic effects of all prior chemotherapy before entering this study, and have an absolute neutrophil count >500/mm3, absolute lymphocyte count >200/mm3, and platelet count >50,000/mm3.
boolean
C0600688 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C2004454 (UMLS CUI [1,3])
C0948762 (UMLS CUI [2])
C3544087 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
GvHD
Item
5. patients must not have active gvhd at the time of protocol entry.
boolean
C0018133 (UMLS CUI [1])
Immunosuppressive therapy
Item
6. patient has not received high dose steroids within the last week or other immunosuppressive drugs within a week (or longer as indicated by the half life of the agent)
boolean
C0038317 (UMLS CUI [1])
C0021081 (UMLS CUI [2])
C3173309 (UMLS CUI [3])
Infections and antibiotics
Item
7. patients must not be infected at time of protocol entry, and should not be receiving antibiotics (other than prophylactic septra.)
boolean
C0009450 (UMLS CUI [1])
C0003232 (UMLS CUI [2])
HIV Seronegativity
Item
8. patients must not be hiv-positive.
boolean
C0019698 (UMLS CUI [1])
Bilirubin, sgot and prothrombin time
Item
9. patients must have adequate liver function (bilirubin<1.5 mg% sgot<2x normal, normal prothrombin time).
boolean
C1278039 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0033707 (UMLS CUI [3])
Specification: transduced cells
Item
10. patients must have transduced cells available that are demonstrably >20% cd40l expressing fibroblasts and producing>150 pg il-2/10 6 cell/24 hr.
boolean
C0167627 (UMLS CUI [1])
C0021756 (UMLS CUI [2])
C0085295 (UMLS CUI [3])
Informed consent
Item
11. patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. patients or their guardians will be given a copy of the consent form.
boolean
C0021430 (UMLS CUI [1])
Experimental drugs
Item
12. patient must not have received treatment with other investigational agents within the last 4 weeks.
boolean
C0304229 (UMLS CUI [1])
Contraception
Item
13. patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded. the male partner should use a condom.
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Blasts infiltrating bone marrow
Item
1. rapidly progressive/refractory disease (>20% blasts infiltrating the bone marrow)
boolean
C1982687 (UMLS CUI [1])
Life expectancy
Item
2. life expectancy < 10 weeks
boolean
C0023671 (UMLS CUI [1])
Active infection
Item
3. active infection
boolean
C0009450 (UMLS CUI [1])
Concomitant drugs
Item
4. need for concomitant drugs except analgesics
boolean
C2347852 (UMLS CUI [1])
C0332300 (UMLS CUI [2,1])
C0002771 (UMLS CUI [2,2])
Gynaecological status
Item
5. pregnancy or lactation
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
HIV seropositivity
Item
6. seropositive for hiv
boolean
C0019699 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video